Myasthenia Gravis: A New Hypothesis

Alajouanine T. Castaigne P. Nick J. Contamin T. Lhermitte F. (1957). Sur l'existence de signes sensitifs et sensorials au cours de la myasthénic. Rev. neurol., 96, 242

Axelsson J. Thesleff S. (1958). The ‘desensitizing’ effect of acetylcholine on the mammalian motor end-plate. Acta, physiol. scand., 43, 15

Bramwell B. (1892). Atlas of clinical medicine. (a) Vol. 3 p. 110 case xvi. (b) Vol. 1 p. 122. Edinburgh: University Press.

Bramwell E. (1938). Upon the pupil reactions—with special reference to contributions by alumni of the Edinburgh school. Edinburgh post-graduate lectures in medicine. 1, 1, Oliver and Boyd

Buzzard E. F. (1905). The clinical history and postmortem examination of five cases of myasthenia gravis. Brain, 28, 438

Campbell H. Bramwell E. (1900). Myasthenia gravis. Brain, 23, 277

Castleman B. Norris E. H. (1949). The pathology of the thymus in myasthenia gravis. Medicine (Baltimore), 28, 27

Chalmers J. N. M. Boheimer K. (1954). Pure red-cell anaemia in patients with thymic tumours. Brit. med. J., 2, 1514

Churchill-Davidson H. C. Richardson A. T. (1952). Action of decamethonium iodide (CIO) in myasthenia gravis. J. Neurol. Neurosurg. Psychiat., 15, 129

Coers C. Desmedt J. E. (1959). Mise en évidence d'une malformation caractéristique de la jonction neuromusculaire dans la myasthénie. Acta neurol. belg., 59, 539

Collier J. (1930). Oculomotor palsies resulting from infective and toxic processes. Trans. ophthal. Soc. U.K., 50, 244

Comsa J. (1958). Influence of the thymus upon the reaction of the rat to anterior pituitary growth hormone. Nature (Lond.), 182, 728

Coulonjou R. Salaun A. (1952). Sur un syndrome myasthénique fréquemment rencontré chez des chiqueurs de tabac. Sem. Hôp. Paris, 28, 3968

Dale H. H. Feldberg W. (1934). Chemical transmission at motor nerve endings in voluntary muscle. J. Physiol. (Lond.), 81, 39P

Denny-Brown D. (1947). Neurological conditions resulting from prolonged and severe dietary restriction. Medicine (Baltimore), 26, 41

Engbaek L. (1951). Acetylcholine sensitivity in diseases of the motor system with special regard to myasthenia gravis. Electroenceph. clin. Neurophysiol., 3, 155

Erb W. (1879). Zur casuistik der bulbären Lähmungen. Arch. Psychiat. Nervenkr., 9, 325

Goldflam S. (1893). Ueber einen scheinbar heilbaren bulbärparalytischen Symptomencomplex mit Betheiligung der Extremitaten. Dtsch. Z. Nervenheilk., 4, 312

Grob D. (1953). Course and management of myasthenia gravis. J. Amer. med. Assoc., 153, 529

Grob D. Johns R. J. Harvey A. M. (1956). Studies in neuromuscular function. IV. Stimulating and depressant effects of acetylcholine and choline in patients with myasthenia gravis, and their relationship to the defect in neuromuscular transmission. Bull. Johns Hopkins Hosp., 99, 153

Harvey A. M. (1948). Some preliminary observations on the clinical course of myasthenia gravis before and after thymectomy. Bull. N.Y. Acad. Med., 24, 505

Harvey A. M. Shulman L. E. Tumulty P. A. Conley C. L. Schoenrich E. H. (1954). Systemic lupus erythematosus. Medicine (Baltimore), 33, 291

Hoeffer P. F. A. Aranow H. Rowland L. P. (1958). Myasthenia gravis and epilepsy. Arch. Neurol. Psychiat. (Chicago), 80, 10

Jolly F. (1895). Ueber myasthenia gravis Pseudoparalytica. Berl. Klin. Wschr., 32, 1

Lambie A. T. Burrows B. A. Sommers S. C. (1957). Refractory anaemia, agamma-globulinaemia, and mediastinal tumour. Amer. J. clin. Path., 27, 444

Long D. A. (1955). The influence of various hormones upon immune and allergic responses of guinea-pigs to bacterial infection. Proc. roy. Soc. Med., 48, 916

Lowenthal A. Van Sande M. (1956). Nouvelles déterminations des fractions proteiniques dans le sérum de patients atteints d'affections musculaires. Rev. Franç. Etudes clin. biol., 1, 765

Metcalf D. (1956). The thymic origin of the plasma lymphocytosis-stimulating factor. Brit. J. Cancer, 10, 442

Nastuk W. L. Strauss A. J. L. Osserman K. E. (1959). Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. Amer. J. Med., 26, 394

Nowell P. T. Wilson A. Wilson H. (1959). Some effects of extracts of foetal whale thymus glands. Quart. J. exp. Physiol., 44, 229

Oppenheim H. (1887). Ueber einen Fall von chronischer progressiver Bulbärparalyse ohne anatomischen Befund. Virchow's Arch. path. Anat., 108, 522

Querido A. (1929). On myasthenia gravis. J. nerv. ment. Dis., 69, 522

Riker W. F. (1953). Some aspects of the pharmacology of neuromuscular function. Amer. J. Med., 15, 231

Rowland L. P. (1955). Prostigmine-responsiveness and the diagnosis of myasthenia gravis. Neurology, 5, 612

Russell D. S. (1953). Histological changes in the striped muscles in myasthenia gravis. J. Path. Bact., 65, 279

Schrire J. (1959). Progesterone metabolism in myasthenia gravis. Quart. J. Med., 28, 59

Simpson J. A. (1958). An evaluation of thymectomy in myasthenia gravis. Brain, 81, 112

Simpson J. A. Lenman J. A. R. (1959). The effect of frequency of stimulation in neuromuscular disease. Electroenceph. clin. Neurophysiol., 11, 604

Sloan H. E. (1943). The thymus in myasthenia gravis. With observations on the normal anatomy and histology of the thymus. Surgery, 13, 154

Smithers D. W. (1959). Tumours of the thyroid gland in relation to some general concepts of neoplasia. J. Fac. Radiol. (Lond.), 10, 3

Strüppler A. (1954). Experimented Untersuchungen zur Pathogenase der Myasthenie. Z. ges. exper. Med., 125, 244

Taylor J. (1958). Selected writings of John Hughlings Jackson. Vol. 2 p. 372. New York: Basie Books, Inc.

Walker M. B. (1934). Treatment of myasthenia gravis with physostigmine. Lancet, 1, 1200

Weigert C. (1901). Pathologisch-anatomischer Beitrag zur Erbach' en Krankheit (Myasthenia Gravis). Neurol. Zbl., 20, 597

Wintrobe M. M. (1946). Clinical haematology. 2nd ed. p. 572. Philadelphia: Lea & Febiger

Zaimis E. J. Churchill-Davidson H. C. Richardson A. T. (1952). Motor end-plate differences as a determining factor in the mode of action of neuro-muscular blocking substances. Nature (Lond.), 170, 617

Wilson A. Obrist A. R. Wilson H. (1953). Some effects of extracts of thymus glands removed from patients with myasthenia gravis. Lancet, 2, 368